

AMENDMENTS TO THE CLAIMS

Please cancel claims 1-35 and add new claims 36, 37 and 38 as shown below.

1-35. (Canceled)

36. (New) An aerosolized formulation of particles having an aerodynamic diameter in a range of from about 0.5 micron to about 10 micron, comprising:

an electrolyte of a sodium salt of ascorbic acid;

a non-ionized drug chosen from Amphotericin; Estrone; Ribavirin; Fluticasone propionate; Beclomethasone dipropionate; Hexamethyl melamine; Benzodiazepines; Lorazepam; Budenoside; Albuterol; Salmeterol; Fentanyl; Phentanyl base; Cyclosporin; Retinoids; Diazepam; Surfactant protein; Droperidol; Testosterone; Ergotamine; THC and its derivatives; Estradiol; Triamcinolone acetonide; human growth hormone, human growth factor, erythropoietin, alpha-, beta-, and gamma- inteferon, an antibody, a soluble receptor, a cytokine, amylin, pegylated protein, pegylated alpha inteferon, parathyroid hormone, calcitonin, folcile stimulating hormone, and alpha-1 antitrypsin; and a nucleotide sequence wherein the non-ionized drug is characterized by not providing a substantial effect on electrostatic charge of the aerosol as compared to an effect on electrostatic charge obtained from the electrolyte; and

a solvent having the drug and electrolyte dissolved therein, wherein the electrolyte is present in a concentration in a range of about 10^{19} ions per liter or more, wherein said electrolyte concentration is sufficient to substantially eliminate electrostatic charge of said particles within said aerosolized formulation.

37. (New) The aerosolized formulation of claim 36, wherein the electrolyte is present in a concentration of about 10^{19} ions per liter or more.

38. (New) The aerosolized formulation of claim 36, wherein the electrolyte is present in a concentration of about 5×10^{20} ions per liter or more.